&nbsp;

obsp-16-10-20.xml

Oct 2020

Document

obsp-16-10-20.html

Oct 2020

Regimen

ATEZBEVA

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma

New Drug Funding Program

Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma

Drugs Used:

atezolizumab,

bevacizumab

Quick Link(s):

Regimen Monograph

Mar 2022

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

ACAL+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded),

oBINutuzumab (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

ACAL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Document

obsp-26-10-20.xml

Oct 2020

Document

OBSP-26-10-20.html

Oct 2020

Document

OSCCDMeetingAgenda28Sep2020.pdf

Nov 2020

Document

OSCCDMeetingAgenda 30Mar2020.pdf

Nov 2020

Document

OSCCDMeetingAgenda23Sep2019.pdf

Nov 2020

Document